— Improved loss from operations by 81% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged ex-U.S. commercial agreement for Phexxi in Middle East — SAN DIEGO , Aug.
14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM ) today announced financial results for the second quarter and first half of 2024. Highlights include: Acquired global rights to SOLOSEC® (secnidazole) 2g oral granules , a single-dose oral antibiotic FDA approved to treat two common sexual health infections - bacterial vaginosis and trichomoniasis.
Licensed Phexxi® (lactic acid, citric acid and potassium bitartrate) commercial rights in the Middle East to Emirati pharmaceutical company Pharma 1 Drug Store. Partnered with leading telemedicine company Hello Alpha to add Phexxi to its commercial offering as a hormone-free contraception solution for women, especially those on GLP-1s and others looking for hormone-free birth control. Negotiated a 7.
4% lower rebate on Phexxi prescriptions to Medi-Cal, the California state Medicaid program service covering more than 15.4 million lives. Launched a partnership with Modern Remedies, one of the top pharmacies in the Northeast, to dispense Phexxi.
Strengthened intellectual property with the issuance and Orange Book listing of the fifth U.S. patent covering Phexxi.
Delivered net sales of $4.2 million fo.